SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: yosarian_2 who wrote (4302)6/7/2016 1:43:06 PM
From: Biomaven1 Recommendation

Recommended By
scaram(o)uche

  Read Replies (1) | Respond to of 4474
 
Yes, Criz is currently the only approved first line agent for ALK+, which is why it is the comparator against briga in the new front line trial.

But alectinib will get front line approval before that trial is fully enrolled, and so it will be hard to get people to enroll in a trial where they might end up with the much inferior (criz) drug.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News